News ArchivesRead News
Parkinson’s Drug Trial Has Researchers Optimistic
Thursday July 31, 2014
Chicago Sun Times - Results of a Phase I clinical trial of what could be the first vaccine for Parkinson’s disease has experts cautiously optimistic.
Those results were released Thursday by the maker of the drug and the Michael J. Fox Foundation for Parkinson’s Disease.
The disease, a progressive disorder of the nervous system that affects movement, is believed to be caused by abnormal deposits in the brain of a protein that helps nerve cells talk to each other.
Many drugs can make movement easier or alleviate other symptoms of the disease. But no drug has been shown to effectively slow or stop the progression.
The drug being tested is known as PD01A, made by AFFiRiS AG, an Austria-based biotech company. It is supposed to stimulate the body’s immune system to produce antibodies that bind to the protein alpha-synuclein, clearing it from the brain and slowing disease progression.
Phase 1 looked only at whether PD01A was safe and tolerable to the relatively small sample of 32 people with Parkinson’s disease. The drug passed that test.
It was also found to generate alpha-synuclein-specific antibodies in 50 percent of the patients. If that is duplicated on a larger population, it could be a breakthrough for Parkinson’s disease.
“A treatment that could slow or stop Parkinson’s progression would be a game-changer for the five million worldwide living with this disease and the many more who will become at risk as our population ages,” Todd Sherer, CEO of the Michael J. Fox Foundation, said in a statement. The most recent drug trial “is one of the most promising efforts toward that goal.”
Dr. Christopher Goetz, director of the Parkinson’s Disease and Movement Disorders Center at Rush University Medical Center, agreed Phase I of PD01A is “very promising.”
But Goetz, who was not involved in the study, also cautioned that because testing of this drug is in the early stages, it remains to be seen whether increasing antibodies to fight alpha-synuclein actually does anything to effectively treat Parkinson’s disease.
Indeed, not everyone is convinced of that premise. And the findings are considered preliminary because they haven’t been published in a peer-reviewed medical journal.
Dr. Jose Biller, chair of the neurology department at Loyola Medicine, said he was cautiously optimistic at what could wind up being a “significant advance” in how Parkinson’s disease is treated.
“The basic science that is behind this trial is quite robust. And therefore, while nobody can talk about guarantee ….I think that it is a very cogent approach,” he said.
That said, though, Biller, who was not involved in the study, said, “We need to wait for the [follow-up] results.”
The next study will take place in Vienna and focus on assessing the immunological and clinical effects of a boost vaccination. Recruitment is expected to begin September.
Recent NewsJun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis